Christina Curtis

Christina Curtis

Auto-generated profile, based on publicly available information

Christina Curtis

Stanford University, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2012 in Nature
Verified
Journal Article
Open access
PDF file
MGMETABRIC Group
METABRIC Group
CCChristina Curtis
Christina Curtis
SSSohrab P. Shah
Sohrab P. Shah
SCSuet-Feung Chin
Suet-Feung Chin
Gulisa TurashviliGulisa Turashvili
Gulisa Turashvili
SASamuel Aparicio
Samuel Aparicio
The elucidation of breast cancer subgroups and their molecular drivers requires integrated views of the genome and transcriptome from representative numbers of patients. We present an integrated analysis of copy number and gene expression in a discovery and validation set of 997 and 995 primary breast tumours, respectively, with long-term clinical follow-up. Inherited variants (copy number variants and single nucleotide polymorphisms) and acquired somatic copy number aberrations (CNAs) were associated with expression in ∼40% of genes, with the landscape dominated by cis- and trans-acting CNAs. By delineating expression outlier genes driven in cis by CNAs, we identified putative cancer genes, including deletions in PPP2R2A, MTAP and MAP2K4. Unsupervised analysis of paired DNA–RNA profiles revealed novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort. These include a high-risk, oestrogen-receptor-positive 11q13/14 cis-acting subgroup and a favourable prognosis subgroup devoid of CNAs. Trans-acting aberration hotspots were found to modulate subgroup-specific gene networks, including a TCR deletion-mediated adaptive immune response in the ‘CNA-devoid’ subgroup and a basal-specific chromosome 5 deletion-associated mitotic network. Our results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome.

4 April 2012 in Nature
Verified
Journal Article
Closed access
PDF file
SSSohrab P. Shah
Sohrab P. Shah
ARAndrew Roth
Andrew Roth
RGRodrigo Goya
Rodrigo Goya
AOArusha Oloumi
Arusha Oloumi
GHGavin Ha
Gavin Ha
SASamuel Aparicio
Samuel Aparicio

14 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ASAndrea Sottoriva
Andrea Sottoriva
ISInmaculada Spiteri
Inmaculada Spiteri
Sara PiccirilloSara Piccirillo
Sara Piccirillo
ATAnestis Touloumis
Anestis Touloumis
VCV. Peter Collins
V. Peter Collins
STSimon Tavaré
Simon Tavaré
Glioblastoma (GB) is the most common and aggressive primary brain malignancy, with poor prognosis and a lack of effective therapeutic options. Accumulating evidence suggests that intratumor heterogeneity likely is the key to understanding treatment failure. However, the extent of intratumor heterogeneity as a result of tumor evolution is still poorly understood. To address this, we developed a unique surgical multisampling scheme to collect spatially distinct tumor fragments from 11 GB patients. We present an integrated genomic analysis that uncovers extensive intratumor heterogeneity, with most patients displaying different GB subtypes within the same tumor. Moreover, we reconstructed the phylogeny of the fragments for each patient, identifying copy number alterations in EGFR and CDKN2A/B/p14ARF as early events, and aberrations in PDGFRA and PTEN as later events during cancer progression. We also characterized the clonal organization of each tumor fragment at the single-molecule level, detecting multiple coexisting cell lineages. Our results reveal the genome-wide architecture of intratumor variability in GB across multiple spatial scales and patient-specific patterns of cancer evolution, with consequences for treatment design.

29 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KYKathryn E. Yost
Kathryn E. Yost
ASAnsuman T. Satpathy
Ansuman T. Satpathy
DWDaniel K. Wells
Daniel K. Wells
YQYanyan Qi
Yanyan Qi
CWChunlin Wang
Chunlin Wang
HCHoward Y. Chang
Howard Y. Chang

9 February 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAndrea Sottoriva
Andrea Sottoriva
HKHaeyoun Kang
Haeyoun Kang
ZMZhicheng Ma
Zhicheng Ma
TGTrevor Graham
Trevor Graham
MSMatthew P Salomon
Matthew P Salomon
CCChristina Curtis
Christina Curtis
Christina Curtis, Darryl Shibata and colleagues report genomic profiling of 349 individual glands sampled from 15 human colorectal tumors. They observe high within-tumor heterogeneity and mixing of subclones in distant tumor regions, supporting a model whereby tumor growth occurs predominantly as a single expansion, with most detectable subclonal mutations arising during the earliest phases of tumor growth. What happens in early, still undetectable human malignancies is unknown because direct observations are impractical. Here we present and validate a 'Big Bang' model, whereby tumors grow predominantly as a single expansion producing numerous intermixed subclones that are not subject to stringent selection and where both public (clonal) and most detectable private (subclonal) alterations arise early during growth. Genomic profiling of 349 individual glands from 15 colorectal tumors showed an absence of selective sweeps, uniformly high intratumoral heterogeneity (ITH) and subclone mixing in distant regions, as postulated by our model. We also verified the prediction that most detectable ITH originates from early private alterations and not from later clonal expansions, thus exposing the profile of the primordial tumor. Moreover, some tumors appear 'born to be bad', with subclone mixing indicative of early malignant potential. This new model provides a quantitative framework to interpret tumor growth dynamics and the origins of ITH, with important clinical implications.

17 June 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ZHZheng Hu
Zheng Hu
JDJie Ding
Jie Ding
ZMZhicheng Ma
Zhicheng Ma
RSRuping Sun
Ruping Sun
JSJose A. Seoane
Jose A. Seoane
CCChristina Curtis
Christina Curtis
Both the timing and molecular determinants of metastasis are unknown, hindering treatment and prevention efforts. Here we characterize the evolutionary dynamics of this lethal process by analyzing exome-sequencing data from 118 biopsies from 23 patients with colorectal cancer with metastases to the liver or brain. The data show that the genomic divergence between the primary tumor and metastasis is low and that canonical driver genes were acquired early. Analysis within a spatial tumor growth model and statistical inference framework indicates that early disseminated cells commonly (81%, 17 out of 21 evaluable patients) seed metastases while the carcinoma is clinically undetectable (typically, less than 0.01 cm3). We validated the association between early drivers and metastasis in an independent cohort of 2,751 colorectal cancers, demonstrating their utility as biomarkers of metastasis. This conceptual and analytical framework provides quantitative in vivo evidence that systemic spread can occur early in colorectal cancer and illuminates strategies for patient stratification and therapeutic targeting of the canonical drivers of tumorigenesis.